Transdermal delivery of peptides and other biological macromolecules is limited due to skin's inherent low permeability. Here, the authors report the use of a deep eutectic solvent, choline and geranate (CAGE), to enhance topical delivery of proteins such as bovine serum albumin (BSA, molecular weight: ≈66 kDa), ovalbumin (OVA, molecular weight: ≈45 kDa) and insulin (INS, molecular weight: 5.8 kDa). CAGE enhances permeation of BSA, OVA, and insulin into porcine skin ex vivo, penetrating deep into the epidermis and dermis. Studies using tritium-labeled BSA and fluorescein isothiocyanate labeled insulin show significantly enhanced delivery of proteins into and across porcine skin, penetrating the skin in a time-dependent manner. Fourier transform IR spectra of porcine stratum corneum (SC) samples before and after incubation in CAGE show a reduction in peak area attributed to SC lipid content, suggesting lipid extraction from the SC. Circular dichroism confirms that CAGE does not affect insulin's secondary conformation. In vivo studies in rats show that topical application of 10 U insulin dispersed in CAGE (25 U kg −1 insulin dose) leads to a highly significant 40% drop in blood glucose levels in 4 h that is relatively sustained for 12 h. Taken together, these studies demonstrate that CAGE is a promising vehicle for transdermal delivery of therapeutic proteins; specifically, as a noninvasive delivery alternative to injectable insulin for the treatment of diabetes.
However, the efficacy of this route is contingent upon the drug's physicochemical characteristics and pharmacokinetics. Lipophilic drugs that are less than 500 Da in size and require low doses for efficacy are ideal candidates for transdermal delivery. [5] [6] [7] For drugs outside this category, the outermost layer of the skin, the stratum corneum (SC), poses a formidable barrier to drug transport owing to its structurally well-organized corneocytes and lipid layers. [8] [9] [10] Hence, many hydrophilic or macromolecule drugs such as peptides, proteins, and nucleic acids cannot be administered through the skin without reducing barrier properties by either disrupting the SC or altering lipid structure through the use of physical (device based) or chemical (formulation based) penetration enhancement techniques. Among the various techniques, iontophoresis/electroporation (electrically assisted), sonophoresis (ultrasound based), microneedles, laser ablation, and chemical enhancers have been widely investigated to improve permeability of macromolecules. [11] [12] [13] [14] [15] [16] [17] [18] [19] Notwithstanding these developments, toxicities arising due to chemical penetration enhancers, infections resulting from chronic disruption of the SC or occurrence of burns and scars have curtailed their clinical application. [20, 21] For example, Zecuity (sumatriptan iontophoretic transdermal system) marketed by Teva Pharmaceuticals for the treatment of migraine has been recently discontinued due to development of adverse events such as burns and scars. [22] In addition, device based systems can only be used over a limited skin area. [24] Recently, we have shown that deep eutectic solvents (DESs) and ionic liquids (ILs) can enhance transdermal delivery of drugs as well as disrupt/neutralize biofilm-forming bacteria. [23, 24] Furthermore, compared to conventional chemical penetration enhancers such as ethanol, ILs demonstrated lesser toxicity to cells thereby mitigating the issue of skin irritation that is characteristic of many chemical enhancers. [23, 25] DES's are a mixture of compounds that collectively have a lower freezing temperature than individual components while ILs are salts consisting of an organic cation and organic/inorganic anion that are stable and in a liquid form at room temperature.
Among different ILs and DESs tested, choline and geranate (CAGE) demonstrated potent antibacterial activity and significantly improved transdermal delivery of antibacterial drugs without causing notable toxicity to keratinocytes and mice. [23] 
Introduction
The skin provides an excellent route for noninvasive delivery of therapeutic moieties due to its enormous surface area and accessibility. In addition to improving patient compliance, this route can be utilized to avoid first-pass metabolism and achieve controlled and sustained delivery for local or systemic action. [1] [2] [3] Consequently, several transdermal products including drugs such as estradiol, fentanyl, nicotine, testosterone, nitroglycerin, clonidine, and scopolamine are available in the market. [4] However, the efficacy of CAGE in enhancing permeation of biomacromolecules across the skin has not been investigated.
Here, we report for the first time that CAGE, without the use of any additional physical/chemical penetration enhancement techniques, can deliver proteins such as bovine serum albumin (BSA, MW: ≈66 kDa), ovalbumin (OVA, MW: ≈45 kDa), and insulin (INS, MW: 5.8 kDa) across porcine skin and significantly reduce blood glucose levels (BGL) in rats when insulin-CAGE is topically administered. These proteins represent a wide range of molecular weights and hydropathicities (BSA −0.429; OVA −0.001; insulin 0.278). They were used to demonstrate the effectiveness of CAGE as a transdermal delivery vehicle for proteins of varying sizes.
Results

Protein-CAGE Penetration into Porcine Skin
The study was conducted to assess whether CAGE enhances delivery of macromolecules into the skin. Using confocal microscopy, penetration of fluorescein isothiocyanate (FITC)-labeled BSA, OVA, and insulin into the epidermis and dermis was evaluated and found to be significantly higher in the presence of CAGE compared to phosphate buffered saline (PBS) (Figure 1) , suggesting CAGE facilitates delivery of large proteins into deep skin layers. The penetration of BSA, OVA, and insulin from CAGE was also compared with that from commonly used chemical penetration enhancers (CPEs) such as diethylene glycol monoethyl ether (DGME, Transcutol) and ethanol. [20, [26] [27] [28] In all cases, penetration of BSA, OVA, and insulin was significantly higher in the presence of CAGE than the CPEs, implying that CAGE is more effective in enhancing permeation of proteins across the skin compared to these widely used CPEs.
Quantitation of Protein-CAGE Penetration through Porcine Skin
The ability of CAGE to enhance macromolecule skin penetration was quantitatively assessed using tritium ( 3 H) labeled BSA (Figure 2 ) and FITC-labeled insulin (Figure 3 ). CAGE significantly enhanced 3 H-BSA penetration into and through the deep layers of porcine skin (measured as 3 H-BSA delivery to the acceptor fluid of the Franz diffusion cell). Specifically, 3 H-BSA delivered to the epidermis (2.84 ± 0.59 µg cm −2 ) and dermis (1.61 ± 0.09 µg cm −2 ) was significant after 12 h compared to PBS controls (epidermis: 0.08 ± 0.01 µg cm −2 and dermis: 0.04 ± 0.04 µg cm −2 ). The 3 H-BSA delivery in 24 h to the dermis of CAGE-BSA treated skin was similar to earlier time points at 1.18 ± 0.01 µg cm −2 but was significantly higher to the acceptor compartment (3.50 ± 0.36 µg cm −2 ). After A) FITC-BSA, B) FITC-Insulin, or C) FITC-OVA. FITC-proteins were suspended in 1 mL of PBS, CAGE, PBS:DGME, or PBS:Ethanol and applied to porcine skin in a Franz diffusion cell. After 24 h at 37 °C, confocal imaging of 20 µm sections at 10× magnification showed FITC-protein penetration into the dermis layer for the CAGE samples but not in the PBS or CPE controls. Scale bar: 300 µm.
(3 of 11) 1601411 48 h, 3 H-BSA delivered to the dermis (1.72 ± 0.17 µg cm −2 ) and acceptor was increased (6.02 ± 1.04 µg cm −2 ), indicating that CAGE-mediated transport through the dermis may be time dependent (Figure 2A ). Total amounts of 3 H-BSA transported into the skin after 6 and 12 h were distributed approximately evenly between the SC and epidermis/dermis/acceptor (E/D/A) (6 h: 45% in SC, 55% in epidermis/dermis/acceptor, 12 h: 51% in SC, 49% in epidermis/dermis/acceptor). At 24 and 48 h, the distribution was significantly skewed toward the deeper skin layers, with at least 80% present in the epidermis, dermis, and acceptor fluid ( Figure 2B ). Skin penetration of 3 H-BSA in PBS was negligible at all time points; testing was suspended after 24 h ( Figure 2C ). Compared to CPEs such as ethanol and DGME at 50% concentrations, neat CAGE exhibi ted significantly higher penetration of BSA into and across the dermis ( Figure 2D ).
CAGE also significantly enhanced FITC-insulin penetration into porcine skin, with significant penetration into the dermis at 24 h: 5.46 ± 0.04 µg cm −2 ( Figure 3A ) and 48 h: 17.22 ± 1.43 µg cm −2 ( Figure 3B ). A larger portion of the insulin fraction delivered was present in the epidermis/ dermis/acceptor fluid for insulin compared to BSA (93% at 24 and 96% at 48 h). The difference in molecular weights between BSA and insulin may have contributed to this effect ( Figure 3C ).
Fourier transform (FT)-IR Spectroscopy of Stratum Corneum before and after CAGE Treatment
To evaluate the effect of CAGE on the SC structure, FT-IR studies were performed (Figure 4) . It was observed that neat CAGE, BSA-CAGE, and INS-CAGE reduced the area of the 2850 and 2920 cm −1 peaks which are indicators of the SC lipid content, while PBS, BSA-PBS, and INS-PBS did not. [29] A decrease in the peaks of CH 2 symmetric stretching at 2850 cm −1 or asymmetric stretching at 2920 cm −1 are indicative of lipid extraction. [30, 31] This suggests that CAGE acts as a lipid extractor to improve permeability of drugs across the skin. All spectra were deconvoluted into individual peaks ( Figure 5 ) to facilitate comparison of the pre-and post-incubation spectrum. In the SC sample, before application of protein-CAGE, two to four peaks are observed to contribute to the 2850 and 2920 cm −1 absorbance peaks, respectively. Post-incubation, all peaks' absorbance was significantly reduced. Inspection of FT-IR spectra of the individual proteins or neat CAGE show that they contain a few peaks in the region of 2800 to 3000 cm −1 , however, neither of the proteins (BSA or insulin), nor CAGE contain peaks at . A more detailed assignment of peaks is beyond the scope of this study, but it appears that a CAGE peak around 2930 cm −1 may contribute to both post-application SC spectra. While absorbance spectra of residual protein or CAGE in the SC sample may contribute to the post-application SC spectra, overall there was a significant reduction in peak areas at 2850 and 2920 cm −1 .
Assessment of Insulin Stability in CAGE
Circular dichroism (CD) spectrophotometry was performed in order to determine the effect of CAGE on the structure of insulin. Stability of insulin was determined by examining the secondary structure of insulin after incubation in CAGE. Secondary protein structures (alpha helices, beta sheets, and random coils) give rise to characteristic shapes in a CD spectrum. Since insulin is made up of alpha helices only, it yields characteristic double negative troughs at 208 and 222 nm in a CD spectrum. [32, 33] The alpha helical conformation of insulin was retained after incubation in CAGE at 4, 25, and 37 °C indicating that insulin remains in its physiologically active conformation when suspended in CAGE (Figure 6 ). However, it should be noted that CAGE is a poor solvent for CD, exhibiting low transparency in the wavelength range of interest, so insulin was recovered from CAGE by repeated washing with PBS.
In Vivo Efficacy of Insulin-CAGE Topical Application
The study was conducted to evaluate the effectiveness of CAGE in delivering therapeutic proteins such as insulin across the skin of rats. The efficacy of the formulation was compared to formulation controls as well as to subcutaneously injected insulin, which is the route of administration currently used for insulin.
Animals did not show any significant decrease in BGL over time with CAGE application alone (Figure 7) . During the first 6 h of study, blood glucose decrease was insignificant, less than 5% (95.7 ± 5.04%), followed by a maximum drop of 15% (85.4 ± 3.8%) at the end of 12 h. Application of 10 U mL −1 insulin in PBS (≈25 U kg −1 body weight) on the skin did not bring about a significant drop in BGL; a 7% drop (93.2 ± 3%) was observed in 6 h followed by a 12% drop (88.1 ± 2.3%) at 12 h. Contrarily, rats subjected to a 10 U mL −1 insulin-CAGE (≈25 U kg −1 body weight) treatment demonstrated an immediate 25% drop in BGL to 73.5 ± 5.2% within 2 h of formulation application. The highest decrease in BGL of around 40% was observed at 4 h (59.5 ± 5.6%). Beyond 4 h, the blood glucose increased slightly and later plateaued to about 70% of initial levels over the next 8 h. In comparison, rats subcutaneously injected with 1 U kg −1 insulin showed a rapid and maximum 45% decrease in blood glucose in 1.5 h (54.93 ± 7.06%) that rose slightly to 40% in 2 h to 59.8 ± 6.25% and returned to 100% at 4 h. Thereafter BGL slowly decreased by about 12% (87.72 ± 0.75%) in 6 h to around 20% (80.41 ± 3.38%) in 12 h. It is noteworthy that unlike injected insulin, the blood glucose drops at 4 h with insulin-CAGE was relatively sustained over the period of study with only a 10% increase over time.
The insulin-CAGE formulation demonstrated a high significant difference in efficacy at 4 and 6 h compared to insulin-PBS (p < 0.001) while an overall high significant difference between the formulations was observed from 2 h onwards (p < 0.01).
Discussion
Increasing knowledge of the human genome and an upsurge in scientific innovation has bolstered the development of biologics . CAGE improves skin penetration of insulin. CAGE significantly enhances insulin penetration to the dermis compared to PBS control. A) 24 h (**p < 0.005); B) 48 h (*p < 0.04); and C) total penetration amount of insulin into skin after CAGE treatment. White and black bars represent the total of SC 1-10 and combination of the epidermis, dermis, and acceptor, respectively. Data represented as mean ± SE for n = 3.
(5 of 11) 1601411 such that they constitute one-third of every new drug approved over the last decade. [34] Peptide and protein drugs including monoclonal antibodies, vaccines, and recombinant proteins are now extensively used for prevention/treatment of infectious diseases, diabetes, and cancer, among many others. However, instability issues such as aggregation, oxidative/hydrolytic/ proteolytic degradation and poor permeability across biological membranes necessitate parenteral administration to improve bioavailability, but in the process hamper patient compliance. [35] In addition, short half-lives of many peptide/protein drugs require frequent injections resulting in cumbersome regimes that result in poor patient compliance. [36, 37] Transdermal route provides a noninvasive alternative to injectable formulations. In addition to being painless, it enables both local and systemic delivery of therapeutics in a safe and controlled manner for a prolonged period of time, with the option of discontinuing treatment at any point. [5, 38] Skin has certain advantages over other noninvasive routes such as oral delivery which suffers from hepatic first pass metabolism, low oral absorption/bioavailability requiring frequent intake of large doses, or drug-dependent gastrointestinal irritation. [38] Passive transdermal delivery, however, is limited to small molecules (ideally < 500 Da) with octanol-water partition coefficients (log P) between 1 and 4. [39] Therefore, large hydrophilic molecules including many therapeutic proteins and peptides such as insulin demonstrate negligible permeation through the skin. To improve skin penetrability, physical/chemical enhancers such as electricity, ultrasound, microneedles, dimethyl sulfoxide (DMSO), urea, azone, pyrrolidones, alcohols, oils, and fatty acids are often used. [18, 21, 40, 41] Although effective, concomitant irritation at the site of application and toxicity has impeded clinical utility of chemical penetration enhancers. [40] In this study, we present CAGE as a novel transdermal delivery material that can significantly improve penetration of proteins through the skin. Specifically, CAGE retains the structure of proteins such as insulin while enhancing its permeability across the skin to significantly reduce blood glucose levels in rats. Therefore, this material has potential for development as a transdermal insulin formulation for the treatment of diabetes.
In our previous study using CAGE, we reported a significant five-fold enhancement in skin absorption of cefadroxil (a broad spectrum antibiotic), compared to control. [24] Cefadroxil, being a small molecule drug (MW 381Da), is innately more suitable for transport and absorption across the skin compared to macromolecules. [6] In the present study, we demonstrate that www.advhealthmat.de
Adv. Healthcare Mater. 2017, 6, 1601411 www.advancedsciencenews.com Figure 5 . Deconvoluted FT-IR spectra for the region indicative of stratum corneum (SC) lipid content before and after application of protein-CAGE shows a reduction in the deconvoluted peaks at 2850 and 2920 cm −1 . The same SC sample before and after incubation in A) BSA-CAGE or B) INS-CAGE for 24 h followed by washing with PBS and drying. Inset graphs show magnification. C) Reference FT-IR spectra of insulin powder, BSA crystals, and neat CAGE (no stratum corneum).
(7 of 11) 1601411 CAGE delivered proteins significantly larger than 500 Da MW to the deep sites of the skin (epidermis and dermis). Physical methods such as ultrasound, iontophoresis, and microneedles have been shown to enhance transdermal delivery of proteins. Demir et al. used sodium alginate microneedles to deliver BSA across the skin and found a 15.4-fold improvement in permeation compared to needle free sodium alginate patches. [42] Chen et al. reported that BSA loaded chitosan microneedle patches led to sustained release of BSA for 8 d while Lee et al. and Sullivan et al. demonstrated that microneedles that "dissolve" in the skin could be used for transdermal delivery of BSA and lysozyme. [43] [44] [45] Prausnitz et al. encapsulated influenza vaccine in dissolving microneedle patches made from polyvinylpyrrolidone and found that the vaccine was not only stable long-term but also was effectively delivered across the skin. The formulation exhibited superior immune response compared to the same dose via intramuscular injection. [46] [47] [48] In addition, the same research group used these microneedles made using polyvinyl alcohol and sucrose to successfully deliver tetanus, rabies and ebola vaccines along with synthetic vaccines made of layer-by-layer microparticles against respiratory syncytial virus. [49] [50] [51] [52] On the other hand, Donnelly et al. used "super swelling" microneedles made of hydrogel forming polymers (Gantrez S-97, polyethylene glycol and Na 2 CO 3 ) to deliver 0.32 g OVA across the skin of Sprague Dawley rats. [53] A peak plasma concentration of OVA was observed in 1 h that was sustained for another 5 h. These studies suggest that microneedles are one of the promising tools for enhancement of transdermal delivery for several types of macro molecules. Colloidal formulations have also been shown to enhance transdermal skin penetration. [54] [55] [56] Results presented here demonstrate that delivery of macromolecules can be effectively achieved without the use of any specific delivery devices or the need to design complex formulations.
In the present study, the transport rate of BSA was found to be 0.19 µg cm −2 h −1 with a total transport of 9.34 µg cm −2 after www.advhealthmat.de Adv. Healthcare Mater. 2017, 6, 1601411 www.advancedsciencenews.com Figure 6 . Circular dichroism spectra of insulin in CAGE or PBS. Insulin was found to be stable in CAGE. Human insulin (100 U) was suspended in 1 mL of CAGE and incubated under refrigeration (4 °C), room temperature (25 °C), or physiological relevant temperature (37 ° C) for 17 h. Circular dichroism spectra in the far-UV region of each sample compared to an insulin-PBS control showed no change in insulin secondary structure. In vivo evaluation of the efficacy of CAGE as transdermal insulin delivery material. Percent change in BGL with time after administration of various formulations in nondiabetic rats. Animals were fasted prior to and during the 12 h period of study. Topical application of CAGE alone (0 U kg −1 insulin, green triangles); insulin in buffer (10 U mL −1 as 25 U kg −1 body weight, red squares); insulin in CAGE (10 U mL −1 with total dose 25 U kg −1 body weight, blue circles); and subcutaneous insulin injection (1 U kg −1 insulin, magenta inverted triangles) was performed. BGL from the tail vein was determined for 12 h at real time and data plotted as percent change in BGL with respect to the baseline (0 h) BGL. Data represented as mean ± SE (n = 6 for transdermal groups; n = 3 for subcutaneous injection group). BGL resulting from the insulin-CAGE application showed a highly significant statistical difference compared to insulin in buffer at 4 and 6 h (p < 0.001) and from 2 h onwards (p < 0.01).
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Adv. Healthcare Mater. 2017, 6, 1601411 www.advancedsciencenews.com 48 h. For insulin, the rate was 0.57 µg cm −2 h −1 with a total transport of 28.35 µg cm −2 . Cormier et al. reported the formation of skin micropathways upon bidirectional stretching of the skin which thereby enhanced transdermal delivery of a 1 kDa decapeptide in hairless guinea pigs from 9.8 to 27.9 µg cm −2 h −1 . [57] The delivery rate of another decapeptide, leutinizing hormonereleasing hormone, was found to be 9.87 µg cm −2 h −1 with pulsed DC iontophoresis. [58] In comparison to these studies, the transport rate of BSA across the skin using CAGE is slower. This is due to the differences in the molecular weights (≈1 kDa decapeptides vs 66.5 kDa BSA) as well as SC disruption mechanisms between CAGE and other techniques. As inferred from FT-IR studies, CAGE is postulated to enhance drug transport through extraction of SC lipids. As an SC lipid extractor, the effect of CAGE on skin may be more gradual compared to a device. However, CAGE can be easily applied to large skin areas, which is challenging for device-based systems.
Efficacy of CAGE in delivering proteins across the skin was evaluated in vivo using insulin as a model protein. A highly significant 40% drop in BGL was observed in 4 h after insulin-CAGE application to rat skin, compared to other formulation controls. Interestingly, unlike injected insulin, efficacy was relatively sustained over the period of study, suggesting that CAGE can be used to achieve long-term glycemic control, thereby precluding the need for frequent insulin injections and notably improving compliance among diabetic patients. Previously, transdermal delivery of insulin has been achieved using various physical enhancement techniques. Application of low frequency ultrasound was found to improve transdermal delivery of 100 U mL −1 insulin in hairless diabetic rats, the extent of which depended on the length of sonophoresis. [13] In another study, Qin et al. showed that pretreatment with microneedles followed by 50 U mL −1 insulin application resulted in a 45% drop in BGL in diabetic rats. [59] Martanto et al. used microneedles to aid transport of 500 U mL −1 insulin across the skin of diabetic hairless rats and observed up to 80% drop in BGL. [60] Chen et al. encapsulated insulin in positively charged nanovesicles and iontophoretically delivered 80 IU insulin through microneedles, thus combining nanotechnology with iontophoresis and microneedle technology. The group observed a 66%-77% drop in BGL in 4-6 h. [61] Hollow microneedles used by Prausnitz and co-workers to deliver insulin lispro intradermally, showed peak plasma concentration at around half the time compared to subcutaneous catheter infusion and higher blood glucose lowering efficacy in type 1 diabetic patients. [62] Apart from physical enhancers, chemical permeation enhancers can also improve transdermal delivery of macromolecules. For example, ethanol increased transdermal delivery of thyrotropin-releasing hormone analog by twofold while skin penetrating peptides coadministered with unfractionated heparin increased protein flux by 24-to 36-fold compared to protein alone. [63, 64] However, it is to be noted that chemical enhancers have more successfully been used mostly for small molecule delivery, as they do not provide similar degrees of penetration enhancement as physical enhancement methods. [65] This notion was corroborated in our study where no improvement in penetration of FITC-BSA, FITC-OVA, or FITC-insulin across the skin was observed in the presence of CPEs such as ethanol or DGME, while a significant enhancement in delivery of these proteins was noted in the presence of CAGE. Further quantitation of 3 H-BSA penetration into different layers of the skin after 24 h treatment with different materials also demonstrated significantly higher accumulation of BSA in the dermis and acceptor chamber when the protein was delivered using CAGE compared to PBS or aforementioned CPEs. This accumulation of 3 H-BSA using CAGE was noted to be a time-dependent process with more accumulation in the stratum corneum up to 12 h, followed by higher accumulation in the epidermis, dermis and acceptor chambers at longer time points (24 and 48 h) . Additionally, penetration into the dermis after 24 and 48 h was significantly higher for FITC-insulin delivered using CAGE compared to PBS. Other formulations such as ultradeformable lipid vesicles (transferosomes), liposomes, ethosomes, niosomes, and lipidated proteins have also shown promise as transdermal delivery vehicles for protein drugs. [66] [67] [68] [69] For effective transdermal delivery, it is incumbent that proteins are not significantly modified to compromise bioactivity and permeation enhancers do not denature proteins or cause skin irritation. In the present study, we use CAGE as a safe and effective transdermal delivery vehicle that retains protein secondary conformation and significantly improves insulin delivery in rats compared to formulation controls. Previous histopathological and toxicity studies in rats and mice showed no observable skin irritation or toxicity upon CAGE application. [23] Preparation of protein-CAGE formulation is a one-step process requiring simple dispersion of dry weight protein in neat CAGE, thus eliminating need for chemical modification of proteins or cumbersome multistep formulation processes. Compared to aforementioned studies, a relatively low insulin dose (10 U) was used in the animal study that led to significant and sustained decrease in BGL. Based on the FT-IR studies we postulate that CAGE improves permeability through SC lipid extraction/membrane fluidization, a quintessential chemical enhancer mechanism of action as seen for DMSO, alcohols, azones, and fatty acids among others. [20, 70, 71] However, additional studies using small and wide angle X-ray diffraction and other techniques are required to understand the exact mechanism of action of CAGE. [72] Application of neat CAGE to rats did not produce a significant drop in BGL, indicating no adverse blood glucose lowering effect of CAGE. The noteworthy efficacy of CAGE in transporting large macromolecules such as BSA, OVA, and insulin across the skin opens the possibility for a more patient compliant treatment approach for many chronic conditions such as diabetes, osteoporosis, and growth deficiency that currently require frequent injections.
Conclusion
Transdermal delivery of therapeutic proteins and peptides is challenging due to very low permeability of these macromolecules across the skin. Traditionally, various physical enhancement techniques have been used to address the delivery challenge. In this study, we demonstrate the effectiveness of CAGE deep eutectic solvent as a potential transdermal delivery vehicle for therapeutic proteins and peptides. CAGE was found to enhance permeability of large macromolecule drugs through the skin both ex vivo and in vivo, in part by extracting lipids from the stratum corneum. Topical administration of 25 U kg −1 insulin in CAGE demonstrated similar peak efficacy as 1 U kg −1 subcutaneous administration and efficacy was sustained for a prolonged period. The formulation is easy to prepare and can be stored at room temperature for several hours without compromising protein secondary structure. Additional studies further investigating CAGE's mechanism of action, long-term stability, toxicity upon chronic use, and investigation of insulin-CAGE efficacy in diabetic rats are required before consideration for further development. In conclusion, the study suggests that CAGE can be used as a transdermal alternative to injectable protein formulations that will significantly improve the quality of lives of thousands of people suffering from various chronic diseases worldwide.
Experimental Section
Materials: Geranic acid, choline bicarbonate, BSA, FITC-insulin, FITC-BSA, and DGME were purchased from Sigma-Aldrich (St. Louis, MO, USA). FITC-OVA was purchased from Thermo Fisher (Rockford, IL, USA). Human insulin was purchased from Sigma-Aldrich (St. Louis, MO, USA). Tritium labeled BSA ( 3 H-BSA) was purchased from American Radiolabeled Chemicals Inc. (St. Louis, MO, USA). Porcine skin was obtained from Lampire Biological Laboratories (Pipersville, PA, USA). The blood glucose measuring meter (Aimstrip plus) and strips were bought from Fisher Scientific (Pittsburgh, PA, USA). Male Wistar rats weighing between 350 and 450 g were purchased from Charles River Laboratories (Wilmington, MA, USA).
Preparation of CAGE: CAGE was prepared as per our previous study. [23] Briefly, two equivalents of neat geranate (20 g, 0.119 mol), recrystallized at least five times at −70 °C in acetone, were added to one equivalent of choline bicarbonate (80 wt% solution, 12.274 g, 0.059 mol) in a 500 mL round-bottom flask. The mixture was stirred at 40 °C until CO 2 production ceased. Remaining water was removed via rotary evaporation at 60 °C for 20 min, and further dried in a vacuum oven for 48 h at 60 °C. Physical characterization at 25 °C showed good agreement with previous values: density, 0.986 g mL −1 ; conductivity, 0.0443 mS cm −1 (Horiba DS-71 meter, Irvine, CA, USA). [23, 24] The NMR spectra (collected using a 500-MHz Varian instrument, Palo Alto, CA, USA) was also in good agreement with previous preparations: 1 H NMR (DMSO-d 6 ), δ5.60 (s, 2H), 5.07 (t, J = 6.1, 2H), 3.86 (t, J = 6.6, 2H), 3.42 (t, J = 6.6, 2H), 3.12 (s, 9H), 2.57 (m, 4H), 2.01 (m, 4H), 1.97 (s, 6H), 1.73 (s, 2H), 1.64 (s, 6H), and 1.57 (s, 6H); 13 C NMR (DMSO-d 6 ), δ170.1, 150-1, 131. 5, 124.1, 122, 67.6, 55.5, 53.6, 53.5, 32.8, 25.9, and 17.9 .
Protein-CAGE Penetration in Porcine Skin using Franz Diffusion Cells and Confocal Microscopy: Ex vivo penetration into skin samples was measured according to previously published methods using Franz diffusion cells (FDC). [17] The acceptor chamber of a FDC was filled with PBS. Thawed, washed porcine skin was positioned with the SC facing up, and stretched to reduce folds. Any air bubbles were removed from the acceptor chamber and skin integrity was confirmed by measuring conductivity. The donor chamber was filled with 300 µL of CAGE, 50:50 (v/v) PBS:ethanol, 50:50 (v/v) PBS:DGME, or PBS (control) containing FITC-BSA (1 mg mL −1 ), FITC-OVA (1 mg mL −1 ), or FITC-insulin (1 mg mL −1 , 29 U mL −1 ) and the FDC were incubated for 24 h at 37 °C on a stir plate to provide mixing of the acceptor fluid. Protein loading in the samples was 0.1% (w/w). Skin samples were harvested after 24 h, frozen in optimum cutting temperature compound, and sectioned into 20 µm thick slices using a cryostat (CM1850 Leica Biosystems, Buffalo Grove, IL, USA). The tissue sections were mounted on slides that were positively charged to help them adhere to the glass slides (Fisher Scientific, Pittsburgh, PA, USA) and imaged on a confocal microscope (Olympus Fluoview 1000 Spectral Confocal, Tokyo, Japan).
Quantitation of BSA-CAGE Penetration through Porcine Skin: The experimental setup was similar to the one described above. BSA (1 mg mL −1 ) was added to CAGE or PBS (control) and then 3 H-labeled BSA was added to a produce final concentration of 0.5 µCi mL −1 . 300 µL of this solution was added to the donor chamber and incubated for 6, 12, 24, or 48 h at 37 °C with stirring. For tests using DGME or ethanol, a 50:50 solution with PBS was prepared as previously described. BSA and 3 H-labeled BSA were added at the same concentrations noted above, and porcine skin-containing diffusion cells were dosed and incubated for 24 h. At the end of incubation period, the donor solution was removed and the skin was washed with PBS and dried. Tape stripping was used to separate the SC from the epidermis. A total of ten strips, each corresponding to a SC layer, removes most of the SC. The epidermis was removed from the dermis using a surgical scalpel. Samples from the SC, epidermis, and dermis layers and from the acceptor solution were incubated in Solvable (Perkin-Elmer, Waltham, MA, USA) overnight, and the concentration of the 3 H-labeled BSA was measured using a scintillation counter (Tri-Carb 2100 TR, PerkinElmer, Waltham, MA, USA).
To measure insulin-CAGE penetration, FITC-insulin (1 mg mL −1 ) was added to CAGE and 300 µL was applied to porcine skin in a diffusion cell and incubated for 24 and 48 h. Separate skin layers were obtained as above and samples were incubated in 3 mL of 1:1 PBS:methanol overnight, centrifuged (5 min, 14 000 × g) and the concentration of FITCinsulin was measured against a calibration standard curve in triplicate using a plate reader and 96 well black plate with a clear bottom (M220 Infinite Pro, Tecan, Männedorf, Switzerland).
FT-IR of Stratum Corneum: The SC was separated from full thickness skin using published methods. [24] In brief, the epidermis was separated from the dermis of a skin sample soaked in a heated water bath. Trypsin was used to digest the epidermis from the SC, which was then washed in PBS and dried at room temperature for 72 h.
FT-IR was performed on SC samples to determine the effect of CAGE on SC structure. A control FT-IR spectrum (Nicolet iS10 FT-IR with a Smart Diamond ATR accessory) was obtained for each 1.5 cm × 1.5 cm SC piece, then incubated for 24 h with 2 mL of PBS or CAGE alone, and PBS or CAGE with BSA or insulin added (1 mg mL −1 ). The SC samples were rinsed by soaking in 5 mL PBS 3 times and dried for 72 h at room temperature. A second FT-IR spectrum was taken for each SC sample and compared to the pretreatment spectrum to evaluate the effect of CAGE alone or protein-CAGE on the SC structure. FT-IR spectra of human insulin powder, BSA crystals, neat CAGE and PBS were also collected for reference. Spectra were deconvoluted into individual peaks using the Omnic FT-IR software provided with the Nicolet spectrometer (for FT self-deconvolution) and OriginPro (OriginLab, Northampton, MA, USA) for peak finding and deconvolution.
Assessment of Insulin Stability in CAGE: Samples containing human insulin (100 U, 3.5 mg) suspended in CAGE (1 mL) were incubated at physiological temperature (37 °C), room temperature (25 °C), or under refrigeration (4 °C) for 17 h in 1.5 mL microcentrifuge tubes. Samples were then centrifuged for 10 min at 10 000 × g and the CAGE was removed via pipetting, taking care not to disturb the soft insulin pellet in the bottom of the tube. The pellet was washed with 1 mL PBS and centrifuged again. PBS-CAGE was pipetted from the tube, and washing/ centrifugation steps were repeated until the insulin did not form a pellet in the tube during centrifugation. Circular dichroism spectrophotometry (Jasco J-1500, Easton, MD, USA) was performed to collect spectra in the far-UV region (190-250 nm) using rectangular quartz cells with a 1mm path length (Starna Cells, 1-Q-1, Atascadero, CA, USA) loaded with 400 µL of sample. Insulin in PBS was used to collect a control spectrum.
In Vivo Efficacy of Insulin-CAGE Topical Application: In vivo experiments were performed in accordance with the University of California Santa Barbara animal care committee guidelines and to the Guide for the Care and Use of Animals of the Institute of Laboratory Animal Resources, National Research Council.
Male Wistar rats (350-450 g) were fasted overnight for a period of 8 h but given access to water ad libitum. The following day the animals were divided into groups of 6 and a 5 cm × 5 cm portion of hair from the animals' backs was clipped. To the exposed skin, ≈1 mL of different treatments were applied that included CAGE alone, 10 U mL −1 insulin in PBS and 10 U mL −1 insulin in CAGE. The site of application was covered with a gauze and tape to prevent drug loss during the period of study. To a fourth group of three animals, 1 U kg −1 insulin was injected subcutaneously. Compared to subcutaneously injected insulin, a higher transdermal insulin dose was utilized to account for loss of drug dose during transit across the skin layers, owing to skin's inherent low permeability for protein molecules. BGL from the tail vein was measured every 2 h for a total period of 12 h using a commercial blood glucose meter. Results were analyzed with respect to initial BGL (at 0 h) and plotted as percent change in blood glucose versus time. All results were represented as mean ± standard error (SE).
Data Analysis: The data were represented as mean ± SE plotted using Graphpad (Prism 6.0 and 7.0, GraphPad Software, LaJolla, CA). For statistical analyses, Student's t-test was used and a value of p < 0.05 was considered statistically significant.
